Zafgen Inc. (NASDAQ:ZFGN) Director Frances K. Heller bought 10,000 shares of Zafgen stock in a transaction dated Friday, July 22nd. The stock was purchased at an average price of $2.99 per share, with a total value of $29,900.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $29,900. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Several analysts have recently issued reports on ZFGN shares. Zacks Investment Research upgraded shares of Zafgen from a “hold” rating to a “buy” rating and set a $7.25 target price for the company in a research note on Thursday, May 12th. FBR & Co restated a “buy” rating and set a $20.00 price target on shares of Zafgen in a research report on Monday, April 4th. Leerink Swann restated a “market perform” rating and set a $6.00 price target on shares of Zafgen in a research report on Wednesday, July 20th. Royal Bank Of Canada restated an “outperform” rating and set a $19.00 price target on shares of Zafgen in a research report on Tuesday, April 5th. Finally, Cowen and Company lowered shares of Zafgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 20th. Six investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $9.22.
Zafgen Inc. (NASDAQ:ZFGN) traded down 0.96% during midday trading on Tuesday, reaching $3.09. 788,029 shares of the company’s stock traded hands. Zafgen Inc. has a one year low of $2.90 and a one year high of $47.98. The stock’s 50 day moving average price is $5.96 and its 200-day moving average price is $6.49. The stock’s market cap is $84.27 million.
Zafgen, Inc is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity.
